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A venous tumor thrombus (VTT) is a potentially lethal complication of renal cell carcinoma (RCC) but 
virtually nothing is known about the underlying natural history. Based on our observation that venous 
thrombi contain significant numbers of viable tumor cells, we applied multiregion whole exome 
sequencing to a total of 37 primary tumor and VTT samples including normal tissue specimens from 
five consecutive patients. Our findings demonstrate mutational heterogeneity between primary tumor 
and VTT with 106 of 483 genes (22%) harboring functional SNVs and/or indels altered in either primary 
tumor or thrombus. Reconstruction of the clonal phylogeny showed clustering of tumor samples and 
VTT samples, respectively, in the majority of tumors. However, no new subclones were detected 
suggesting that pre-existing subclones of the primary tumor drive VTT formation. Importantly, we 
found several lines of evidence for “BRCAness” in a subset of tumors. These included mutations in genes 
that confer “BRCAness”, a mutational signature and an increase of small indels. Re-analysis of SNV calls 
from the TCGA KIRC-US cohort confirmed a high frequency of the “BRCAness” mutational signature 
AC3 in clear cell RCC. Our findings warrant further pre-clinical experiments and may lead to novel 
personalized therapies for RCC patients.
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Metastatic renal cell carcinoma (RCC) is the most lethal urological cancer and characterized by extensive 
genomic intratumoral heterogeneity1,2. In approximately 4–25% of RCC patients, the primary tumor extends into 
the renal vein, the inferior vena cava or as far as the right atrium of the heart, usually under formation of a large 
blood clot3–5. RCC tumor thrombi are subdivided macroscopically according to their consistency into solid or 
friable. The latter has been suggested to be associated with a worse prognosis although this notion has recently 
been challenged6–8. Despite the poor prognosis associated with venous tumor thrombus (VTT) formation if left 
untreated9–11, virtually nothing is known about its natural history.
Clear cell RCC has previously been shown to exhibit a high degree of mutational heterogeneity and patterns of 
branched and convergent clonal evolution1,2. There is evidence that functional and genomic intratumoral hetero-
geneity in RCC is shaped by spatial niches12,13. To what extent these findings apply to RCC with VTT is currently 
not known in detail14.
Herein, we used multiregion whole exome sequencing of RCCs with VTT to characterize the mutational 
landscape of these tumors. We found heterogeneous mutations between primary tumor and VTT, however, our 
results suggest that pre-existing subclones of the primary tumor drive VTT formation. Importantly, we provide 
evidence for homologous recombination defects (“BRCAness”) in a subset of RCCs with VTT, which holds the 
promise for novel personalized therapeutic interventions in patients with this condition including PARP inhibi-
tors, platinum salts or others15.
Methods
Patients. A total of five consecutive patients with RCC and venous tumor thrombus were prospectively 
included after written informed consent and under Ethics committee vote 207/2005 of the University of 
Heidelberg School of Medicine. All patients showed a clear cell histomorphology except patient RCC-VTT-04 
with a papillary type II RCC.
Whole exome sequencing. DNA extraction and whole exome sequencing were performed by GATC 
Biotech (Konstanz, Germany) on an Illumina platform (InView™ Human Exome). Fastq files were aligned against 
the human reference genome (build 37, version hs37d5), using bwa mem (version 0.7.8 with minimum base 
quality threshold set to zero [−T 0] and remaining settings left at default values), followed by coordinate-sorting 
with bamsort (with compression option set to fast (1)) and marking duplicate read pairs with bammarkduplicates 
(with compression option set to best (9)) (both part of the biobambam package version 0.0.148).
The generated bam files were used to identify high-confidence somatic SNVs by applying an in-house analysis 
pipeline based on samtools16 and bcftools (both version 0.1.19) as described earlier17,18. Briefly, samtools version 
0.1.1916 was used for calling all candidate variants (positions where the tumor sample differs from the reference 
sequence). The filter, which usually makes samtools a germline caller, was switched off. Candidate variants were 
postfiltered by custom filters optimized for somatic variant calling. The discrimination between somatic and 
germline variants was performed by looking up the variant position in the matched normal sample.
Results were amended by additional classification of the SNVs into 96 categories according to their triplet 
of the base preceding the SNV, the actual transition/transversion and the following base. For each class it was 
determined whether its SNVs exhibit a sequencing strand bias. For classes with bias, SNVs with less than two 
supporting reads on the strand opposite to the strand exhibiting the biased variants were filtered out. Somatic 
SNVs were called functional, when they were nonsynonymous, occurred within splice sites, or lead to gain or loss 
of stop codons. All SNVs were annotated using Annovar19 (version as of February 2016), dbSNP (build 147)20, 
1000 Genomes21 and EVS (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA 
[version ESP6500SI-V2]) data. Indels were identified with Platypus callVariants (version 0.8.1, parameter settings 
genIndels = 1, genSNPs = 1, bufferSize = 100000 and maxReads = 10000000)22. All indels were annotated using 
Annovar19 (version as of November 2014), dbSNP (build 141)20, 1000 Genomes21 data.
Sequence data for this study is available in the European Genome-phenome Archive (EGA), which is hosted 
by the EBI, under accession number EGAS#00001001950.
Supervised Analysis of Mutational Signatures. A supervised analysis of mutational signatures deter-
mines contributions of known mutational signatures to the mutational catalogue, i.e. counts of nucleotide 
exchanges in their motif context, of a given dataset. As opposed to an unsupervised analysis of mutational sig-
natures, i.e. a discovery method like non-negative matrix factorization (NMF) as used in23, a supervised analysis 
requires much less statistical power, but will not discover new signatures. A software to carry out such an analysis 
was written as an R package (YAPSA – Yet Another Package for Signature Analysis24; manuscript in preparation). 
Due to the low requirements on statistical power, i.e. the number of samples in a cohort and the number of point 
mutations per sample, the supervised analysis of mutational signatures as carried out by YAPSA may be run on 
very small cohorts.
Using YAPSA, a linear combination decomposition of the mutational catalogue with known and predefined 
signatures was computed by non-negative least squares (NNLS), functions for which are implemented in the R 
package lsei25. In order to increase specificity, the NNLS algorithm was applied twice: after the first execution, 
only those signatures whose exposures, i.e., contributions in the linear combination, were higher than a certain 
cutoff, were kept and the NNLS was run again with the reduced set of signatures. As detectability of the different 
signatures may vary, the cutoffs were chosen to be signature-specific.
In the analysis presented here, we used a set of 30 publicly available mutational signatures (http://cancer.
sanger.ac.uk/cosmic/signatures), which were identified in an unsupervised analysis of 10,952 whole exome 
sequenced and 1,048 whole genome sequenced tumor normal control pairs (12,000 pairs in total). We call 
these signatures, which are an extension of the signatures published initially in23, AC1 – AC30 (AC standing for 
Alexandrov COSMIC). The signature-specific cutoffs were determined in a receiver operator characteristic (ROC) 
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analysis using publicly available data on mutational catalogues of the samples included in the initial Alexandrov 
analysis23, consisting of 7,042 tumor normal control pairs (507 from whole genome sequencing and 6,535 from 
whole exome sequencing).
Before running an analysis, YAPSA builds up the mutational catalogues of the samples or cohorts to 
be analyzed by calling the functions mutationContext and mutationContextMatrix from the R package 
SomaticSignatures26. The mutational catalogue was then corrected for different occurrences of the motifs between 
the whole genome and the target capture used for whole exome sequencing of the tumor of our patients.
Copy number alterations (CNAs), tumor cell content (TCC) and ploidy estimation. CNAs were 
inferred from whole exome sequencing data with cnvKit version 0.8.6 (git repository hash: 85774ac)27 with 
default parameter settings.
Heterozygous SNPs were determined as those positions with alternative allele fraction between 0.3 and 0.7 in 
the respective normal sample. Segments which contained at least 20 heterozygous SNPs were further processed 
to infer sample ploidy and tumor cell content along with allele-specific copy number estimates. The segments 
were classified as balanced or imbalanced according to the distribution of the frequencies of the alternative allele 
of the SNPs in the respective segments. If this distribution had a global maximum between 0.45–0.55 a segment 
was called balanced, remaining segments were further separated into two groups – ambiguous segments with 
one density peak outside of the above mentioned interval, and imbalanced segments with two peaks. Ambiguous 
segments were neglected in subsequent steps. For imbalanced segments, the mean B-allele frequency (BAF) of all 
SNPs in the segment that were heterozygous in the germline was estimated using the allele with the higher read 
count as B-allele. Then the mean read count of the B-allele was calculated as product of total coverage and the 
BAF of the respective segment.
Tumor cell content (TCC) and ploidy of a sample were estimated using a method adapted from ACEseq 
(manuscript in preparation). For TCC estimation values in the range of 0.15–1.0 were tested whereas a ploidy 
range between 1 and 6.5 was allowed. For each possible combination of TCC and ploidy, absolute copy numbers 
as well as allele-specific copy numbers and the decrease in heterozygosity (DH)28 were estimated segment-wise. 
Allele-specific copy numbers were calculated as total copy number divided by two for balanced segments and as a 
function of coverage and B-allele read counts in case of imbalanced segments. The weighted mean distance of all 
segments to the next allowed integer copy number state was calculated for total and allele-specific copy numbers. 
Here, allowed means even total copy number states for balanced segments and any integer copy number state 
for imbalanced segments and allele-specific copy numbers. TCC/ploidy combinations requiring negative copy 
number states or a DH larger than 1 for any segment were excluded. Local minima in the weighted mean distance 
were considered as possible TCC/ploidy solution for the sample and were visually evaluated. Additionally, TCC 
was estimated from the mutant allele fraction distribution of somatic SNVs and CNV-based and SNV-based 
estimates were compared.
Due to low TCC, resulting in a weak signal for imbalance detection, some samples required manual adjust-
ments. For the sample RCC-VTT-01 thrombus III (7), regions that were erroneously annotated as balanced by 
the automated detection were reclassified as imbalanced based on the coverage profile and comparison to the 
remaining samples from the same patient. B-allele read counts were recalculated for these segments and a rerun 
of ploidy and TCC estimation was performed. All samples from patients RCC-VTT-02 and RCC-VTT-03 showed 
a low TCC. Only one sample from RCC-VTT-02 (tumor (1)) had sufficient TCC for proper calling of allelic states. 
For all other RCC-VTT-02 samples the restrictions for balanced segments were loosened so they could be fitted 
to uneven copy numbers too to account for undetected imbalances. This lead to a better fit of the copy numbers 
though TCC was still estimated too high based on visual inspection of the BAF profiles and compared to the 
MAF estimates, most likely due to high subclonality or low signal due to the low TCC. RCC-VTT-02 tumor (1) 
was used as reference for the newly obtained calls to evaluate the allele-specific estimates as some of its CNAs 
were also expected to appear in the other samples with lower purity. The new ploidy fits were combined with 
TCCs that were based on the MAF estimates. Good results could be obtained with this approach with respect to 
small deviations from integer copy number states and overall comparison against RCC-VTT-02 tumor (1). For 
patient RCC-VTT-03, all samples showed low TCC (<30%, based on MAF estimates and visual inspection of 
BAF profiles), so no reliable estimates for balanced and imbalanced states could be achieved. As we were missing a 
reference for this case, no allele specific copy numbers could be obtained for this patient. Similar to RCC-VTT-02, 
TCC was based on the MAF distribution whereas the ploidies were estimated with the constraint that the lowest 
observed coverage had to correspond to one copy and the majority of the genome fitted to a diploid state.
HRD (Homologous Recombination Deficiency) and LST (Large Scale Transition) scores estimation. 
For stable HRD and LST scores estimation, copy number profiles were smoothed to reduce oversegmentation caused 
by technical noise. All neighboring segments that rounded to the same total and allele specific copy number and did 
not deviate by more than 0.3 from another were merged. In addition to smoothing of similar segments any segments 
smaller than 3 Mb were merged with their more similar neighbor as suggested by Popova et al.29.
Any switch between copy number states of segments that were larger than 10 Mb and did not correspond to 
full chromosome arms was counted as LST according to Popova et al.29. Additionally, segments that were larger 
than 15 Mb but less than a whole chromosome in length and corresponded to a loss of heterozygosity (LOH) were 
counted for the HRD estimation30.
In case of RCC-VTT-03, only segments with a single copy were taken into account for HRD estimation due to 
the lack of allele-specific copy numbers.
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Heterogeneity analysis. In order to reconstruct the clonal evolution of the tumor samples, the R package 
Canopy version 1.1.1 was used31. Canopy takes two sources of information as input: MAF values of SNVs and 
CNAs. In this project, functional somatic SNVs and smoothed copy number segments (as described above) were 
used. Segments, which were shared by all samples were removed, as they do not contribute to discrimination 
between samples. Additionally, according to the advice of the author of the software, small segments (<1 kbp) 
were neglected, as larger events tend to be more reliable than small ones, especially on exome sequencing data. 
For each patient, the optimal number of subclones K was identified by Canopy based on the Bayes Information 
Criterion (BIC), followed by a Markov chain Monte Carlo (MCMC) based approach to determine a tree topol-
ogy with K leaves and a mutation setting in this tree, which explains the observed mutation pattern with highest 
likelihood. MCMC sampling steps were performed over 50,000 iterations in 30 individual chains (to avoid local 
optima) in a parallelized manner. Mutations defining individual subclones are available upon request.
Immunohistochemistry. Formalin-fixed, paraffin-embedded tissue specimens were provided by the tissue 
bank of the National Center for Tumor Diseases (NCT, Heidelberg, Germany) in accordance with the regulations 
of the tissue bank and the approval of the ethics committee of the University of Heidelberg School of Medicine. 
Paraffin sections were deparaffinized in xylene and rehydrated in a graded ethanol series. Antigen retrieval was 
performed with a steam cooker using retrieval buffer (Target Retrieval Solution, Dako). Primary antibodies used 
were directed against Ki-67 (clone MIB-1, Dako, 1:100), phospho-S6 ribosomal protein S235/236 (Cell Signaling; 
1:100) or γH2AX (clone JBW301, Millipore, 1:100) and were incubated overnight at 4 °C. Immunodetection 
was performed using the Histostain-Plus Detection Kit (3rd Generation, Invitrogen) according to manufacturer’s 
recommendations. Nuclear counterstaining was provided by hematoxylin (Thermo Scientific). Tissue specimens 
were analyzed by two independent observers (L.V.C., M.He.). For statistical analysis, the Mann Whitney U test, 
Wilcoxon rank-sum test or Student’s t test for independent samples were used wherever applicable. Differences 
with a p value of ≤0.05 were considered significant.
All methods were performed in accordance with the relevant guidelines and regulations and experimental 
protocols were approved by the Ethics committee of the University of Heidelberg School of Medicine (206/2005). 
Datasets generated during the current study and not deposited at EGA are available from the corresponding 
author at reasonable request.
Somatic variant calls in the TCGA KIRC-US cohort. Somatic SNV calls from the TCGA KIRC-US 
cohort32 were downloaded from https://portal.gdc.cancer.gov/legacy-archive/files/3e93f2c1–559f-4747-9c53-
30589dbc03f7 as per February 5th, 2018. Samples were filtered for mutational load and only those with more 
than 25 somatic SNVs were kept for the analysis, leaving 400 samples for the analysis. In complete analogy to the 
analysis of mutational signatures of our own samples, a mutational catalog was built, correction for triplet content 
was performed and a supervised analysis of mutational signatures using YAPSA24 was performed.
Results
Venous tumor thrombi contain viable and proliferating RCC cells. In exploratory experiments that 
preceded the multiregion whole exome sequencing study, we analyzed representative samples from 14 RCCs 
with VTT to assess if viable cells were present in the blood clot (Fig. 1). Unexpectedly, we detected a considerable 
number of proliferating Ki-67-positive tumor cells in the venous thrombi (mean 25.6 cells per 40× high-power 
field [HPF]; range, 2.3–88.7 cells/HPF). Moreover, we found tumor cells showing activated growth and survival 
signaling via the PI3K-AKT-mTOR axis as evidenced by positivity for phospho-S6RP S235/236 (mean 4.8 cells 
per HPF; range 0–11.9 cells/HPF).
Figure 1. Tumor thrombi contain vital tumor cells. Representative immunohistochemical staining of a venous 
tumor thrombus for Ki-67 and phospho-S6RP S235/236. The tumor was unrelated to the five RCC-VTT cases 
analyzed. Scale bar = 100 μm.
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Mutational landscape of RCC with VTT. Encouraged by the finding that venous thrombi contain a sub-
stantial amount of viable tumor cells, we performed multiregion whole exome sequencing of a total of 37 samples 
from five consecutive patients with RCC and VTT (Fig. 2) to directly compare the mutational landscape between 
the primary tumor and the corresponding VTT. Four patients were diagnosed with clear cell renal cell carcinoma 
whereas one patient (RCC-VTT-04) had a poorly differentiated type II papillary RCC and, in line with previous 
reports, mutations in NF2 and SETD2 (see below)33,34. The latter patient had a friable tumor thrombus, whereas 
the other four were of solid consistency (Fig. 2).
DNA isolated from normal tissue (n = 5), different locations of the primary tumors (n = 16) and different lev-
els of venous tumor thrombi (n = 16; Fig. 2) were sequenced to >35-fold target coverage (mean target coverage: 
48.7× [range: 37×– 99.5×]; Suppl. Table 1). In all patients, the minor allele frequency (MAF) distribution was 
comparable between samples from the primary tumor and VTT indicating that results were not due to an uneven 
admixture of non-tumorous cells (Suppl. Fig. 1).
Across all samples, we identified 442 somatic functional SNVs and 64 functional indels in a total of 483 genes 
(Suppl. Table 2). Known RCC-associated genes and drivers were mostly found to be mutated in both the primary 
tumor and the VTT (VHL, PBRM1, SETD2, BAP1, PTEN, MTOR and TP53) with the exception of an MTOR 
mutation in RCC-VTT-02 and an ARID1A mutation in RCC-VTT-05 (Fig. 3)32. Among the genes mutated, a 
number of DNA damage checkpoint and repair genes stood out including BAP1, CDK12, CEP164, ERCC1, LIG1, 
POLK, POLM and USP28 (Fig. 3)35–37.
Overall, 106 of 483 genes (22%) harboring functional SNVs and/or indels were heterogeneous between 
primary tumor and thrombus i.e., they were altered only in one but not the other of the two compartments 
(Suppl. Table 2 and Fig. 3). The sum of the number of genes that were mutated exclusively in the primary 
tumor (by somatic SNVs and/or indels) but not the VTT of the same patient was 63 (13% of all altered genes; 
patient-individual numbers ranged from 1 to 24) across all patients. Conversely, a total of 43 genes (8.9% of all 
altered genes) were mutated exclusively in venous tumor thrombi but not in the corresponding primary tumor 
(range from 5 to 13; Suppl. Table 2).
Copy number alterations (CNAs) inferred from exome sequencing data after correction for purity showed a 
loss of chromosome 3p except in patient RCC-VTT-04 with a papillary type II RCC (Suppl. Fig. 2).
Taken together, these results underscore that venous thrombi in RCC contain viable tumor cells with hetero-
geneous mutations, some of which affect genes involved in the cellular response to DNA damage.
Clonal phylogeny in RCC with VTT. We next sought to analyze the relationship between primary tumor 
and VTT in greater detail. To reconstruct the phylogeny of the tumor samples, the R package Canopy was used31. 
With the help of Canopy, we attempted to reconstruct the subclonal evolution of the tumor and subclone con-
tributions to the individual primary tumor and VTT samples. Canopy was applied to the patients individually. 
As input for Canopy, we took the smoothed copy number segment data and the collection of all SNVs which 
were identified as somatic and functional in any of the samples of the respective patient. As shown in Fig. 4, 
this approach was able to model the clonal evolution and waves of mutational events for four of the five tumors 
with time running down vertically from the root to the bifurcations of the phylogenetic tree. RCC-VTT-03 was 
excluded from the analysis with Canopy because of insufficient purity. Each sample consisted of a mixture of 
subclones that are represented as stacked bar plots (Fig. 4, right panels).
In three of the four tumors that entered the final analysis, there was a phylogenetic separation between pri-
mary tumor and VTT (Fig. 4, dendrograms on the left) suggesting an evolutionary distance between the two 
compartments. There were also noticeable differences in the number of subclones and subclonal composition 
modeled by Canopy. Whereas SNVs and CNAs in RCC-VTT-01 and -04 were modeled into three subclones with 
a relatively even admixture in primary tumor and VTT, RCC-VTT-02 and -05 showed a higher number of sub-
clones (up to six) and greater differences in the subclonal composition of a given sample.
Figure 2. Patient characteristics and sampling sites. VTT levels are indicated according to Novick48.
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We next analyzed whether the higher subclonal heterogeneity detected in RCC-VTT-02 and -05 may be 
associated with enhanced replication stress, a major cause of genomic instability and clonal heterogeneity38. An 
immunohistochemical analysis of corresponding primary tumor and thrombus of the five sequenced patients for 
proliferative activity (Ki-67) and signs of an activated DNA damage response (γH2AX; Suppl. Fig. 3) was per-
formed. We found a consistently and significantly (p values between p ≤ 0.05 and p ≤ 0.0005) higher proliferation 
Figure 3. Mutational landscape of RCC with venous tumor thrombus. Functional SNVs (green) and indels 
(orange) in 483 genes are shown (grey indicates absence of a mutation). Numbers in cells describe the number 
of reads carrying the alternative allele and the respective sequencing coverage at this position. Bars on the 
right side of each plot indicate primary tumor-specific (red) or VTT-specific (blue) SNVs and indels. Driver 
mutations are highlighted in red.
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Figure 4. Clonal evolution in RCC with VTT. The clonal heterogeneity for all samples was determined using 
Canopy. Clonal evolution is depicted as a tree, the leaves of which correspond to the subclones denoted by 
“Clone1” up to “Clone6”. The number of leaves corresponds to the optimal number of subclones. The set of all 
mutations (SNVs and CNAs) among all samples of the patient is distributed along the tree in a (heuristically) 
optimal way (“Mut1”–“Mut10”). Each clone carries all the mutations, which can be collected when following 
the path from the respective leaf to the root of the tree. The matrix below the mutation tree shows the subclonal 
composition of each sample (values per line add up to 1). The leaf named “Normal” represents normal tissue 
contamination and has been neglected in further analyses. The contributions of each other subclone to a sample 
are illustrated in a stacked bar plot to the right of the matrix, the colors of which correspond to the colors of the 
leaf labels of the mutation tree. To the left of the matrix, the relationship between the samples with respect to 
subclonal composition (without “Normal”) is illustrated by a dendrogram.
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rate in the venous thrombi in comparison to at least one of the respective primary tumor samples (Suppl. Fig. 3). 
At the same time, tumor cells with γH2AX foci indicating an activated DNA damage response were detected in all 
primary RCCs and corresponding venous tumor thrombi at varying levels (Suppl. Fig. 3). Although a high num-
ber of γH2AX foci-positive tumor cells were detected in RCC-VTT-05, which also showed a high clonal diversity, 
there were overall no fundamental differences between tumors with high clonal diversity in comparison to RCCs 
with lower clonal diversity. This finding suggests that replication stress may not play a major role in shaping clonal 
heterogeneity.
Taken together, these findings indicate that a phylogenetic separation of tumor and VTT can occur without 
new mutations suggesting that pre-existing subclones of the primary tumor drive VTT formation.
Mutational signatures in RCC with VTT. Mutational signatures are an emerging concept in under-
standing cancer genomes and underlying mechanisms of genomic instability23. To further elucidate mutational 
processes in RCC with VTT, we performed a supervised analysis of mutational signatures using the software 
YAPSA24, i.e. an analysis with pre-described mutational signatures taken from http://cancer.sanger.ac.uk/cosmic/
signatures (Fig. 5A).
Mutational signatures can be grouped into different categories including clock-like signatures39, signatures 
associated with mutagenic enzymatic systems or signatures associated with DNA damage repair defects23. In 
the present cohort and in accordance with previous analyses of mutational signatures in RCC23,39, we found a 
high prevalence of signature AC5 indicating metabolic stress in all samples (Fig. 5A). Moreover, we found expo-
sure to signature AC3 indicating homologous recombination (HR) repair defects in multiple samples of three 
of the five patients (RCC-VTT-01, -04, -05; Fig. 5A). Signature AC3, which can be caused by mutations in DNA 
repair genes such as BRCA1 or BRCA2 but also others, has not been reported in RCC before23,39, and may have 
important translational implications since it is known to confer “BRCAness”40. Although no BRCA1 or BRCA2 
mutations were found in the three RCCs with AC3 exposure, the presence of such mutations is not a prerequisite 
for “BRCAness”. Instead we detected mutations in BAP1, CDK12, ERCC1 or PTEN, which have recently been 
implicated in “BRCAness”40. In line with our notion of “BRCAness” in RCC, these genes were found mutated in 
tumors with mutational signature AC3 (RCC-VTT-01, 04, -05; Fig. 3).
Figure 5. Mutational signatures in RCC with VTT. (A) Mutational signature analysis of the five patients. 
The shown signatures represent the following mutational processes: AC1 = spontaneous deamination; 
AC2 = APOBEC action; AC3 = homologous recombination repair defect; AC5 = unknown/metabolic stress; 
AC9 = Pol eta/somatic hypermutation; AC13 = APOBEC; AC17 = unknown. Note the presence of AC3 
indicating defective homologous recombination repair in three of the five patients (RCC-VTT-01, -04, -05). 
(B) Scatterplot of exposures to signature AC3 and indel counts (2–10 bp) per sample. Wilcoxon rank-sum test 
between the two colour-coded groups, p ≤ 0.0001.
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To further corroborate the notion of “BRCAness” in tumors with signature AC3, we analyzed counts of small 
indels of 2–10 bp length. Small deletions of up to 50 bp have been reported to be characteristic for BRCA1/2 muta-
tion associated DNA repair defects41–43. A significant correlation between exposure to mutational signature AC3 
and higher somatic indel counts was detected (Wilcoxon rank-sum test p ≤ 0.0001; Fig. 5B).
In addition, HRD (Homologous Recombination Deficiency) and LST (Large Scale Transition) scores were 
estimated using smoothed copy number profiles. These two scores, however, did not show a significant correla-
tion with AC3 exposure.
Furthermore, we tested whether indel counts and AC3 exposure were dependent on the localization of the 
sample taken (i.e., primary tumor or VTT). No such correlation could be corroborated and we conclude that 
there is no modulating effect of the origin of the specimen in this respect.
Lastly, we sought to determine whether AC3 exposure is a general feature of clear cell RCC. To this end, we 
re-analyzed data from 400 patients of the clear cell RCC TCGA cohort (KIRC-US, patients filtered by a minimum 
of 25 somatic SNVs per sample; https://portal.gdc.cancer.gov/projects/TCGA-KIRC) and found AC3 exposure in 
297 of 400 samples (74.25%; Fig. 6).
In summary, our results show that a subset of RCCs with VTT show signs of “BRCAness” including exposure 
to mutational signature AC3 as well as an increase of small indels. A re-analysis of mutational signatures in the 
TCGA KIRC-US cohort furthermore suggests that AC3 exposure is a frequent finding in clear cell RCC.
Discussion
Herein, we demonstrate that intravenous tumor thrombi in RCC are not simply an accumulation of tumor cells 
of uncertain viability and thrombotic material. Instead, our results indicate that they contain viable tumor cells 
with mutational heterogeneity between primary tumor and VTT. Moreover, we find signs for “BRCAness” in a 
subset of RCCs with VTT.
The mutational heterogeneity within individual RCCs, among patients and between primary tumors and 
venous thrombi is in line with previous reports1,2. RCCs are also known to harbor more than one driver mutation, 
a finding that is confirmed in our study2. Our results furthermore suggest that, despite mutational heterogeneity, 
no additional mutations are required for VTT formation and that pre-existing subclones of the primary tumor 
can drive this process.
“BRCAness” is a relatively recent concept in tumor biology that capitalizes on the fact that defects in error-free 
DNA double-strand break repair by HR repair represent a common outcome of inactivating mutations in a large 
number of genes in addition to BRCA1 or BRCA215,40. The mutational signature AC3, which is associated with 
“BRCAness”, was not found in two large studies on mutational signatures that included RCCs23,39. This most 
likely reflects technical differences since the algorithm to detect mutational signatures used in the present study is 
supervised and highly sensitive for detecting known mutational signatures. A re-analysis of the TCGA KIRC-US 
data confirmed a relatively high frequency of signature AC3 in clear cell RCC. Although we were not able to 
retrieve information on the VTT status in these tumors, the fact that over 70% of tumors showed AC3 exposure 
in comparison to the reported VTT frequency would argue that AC3 exposure is a more general finding in clear 
cell RCC and not specific for RCCs with VTT.
Figure 6. Mutational signatures in the TCGA KIRC-US cohort. Re-analysis of the TCGA KIRC-US cohort 
using 400 samples of the clear cell RCC TCGA cohort (KIRC-US; patients filtered by a minimum of 25 somatic 
SNVs per sample; https://portal.gdc.cancer.gov/projects/TCGA-KIRC). Note the high frequency of mutational 
signature AC3 and AC5. Each bar represents one patient. The y axis depicts the number of mutations. 
Additional signatures represent the following mutational processes: AC4 = smoking; AC6 = defective DNA 
mismatch repair; AC10 = altered POLE activity; AC27 = unknown.
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RCC is not known to frequently harbor mutations in DNA repair genes and is considered largely insensitive 
to DNA damaging agents. In the present study, we did not find any mutations in the “classical” HR repair genes 
such as BRCA1 or BRCA2 although such mutations do exist in RCC44. However, we did find functional SNVs or 
indels in genes linked to either HR gene expression (CDK12) or execution/completion of HR (PTEN, ERCC1)40. 
We hasten to add that other genes or combinations of genes that harbor functional SNVs and indels identified in 
our study could also provide a link to the “BRCAness” signature. Hence, a careful interpretation of the causative 
role of gene mutations is necessary and eventually requires a functional validation.
It is noteworthy that some genomic characteristics that have been found to be associated with “BRCAness”, 
namely the HRD and LST scores, did not show a correlation with mutational signature AC3 in our study. This 
finding could be related to the fact that whole exome sequencing was used, which may lead to an underestimation 
of these LOH-based scores or may reflect a less stringent correlation between signature AC3, “BRCAness” and 
LST/HRD scores in RCC in comparison to breast or ovarian cancer with germline BRCA1/2 mutations.
“BRCAness” has been shown in other tumor entities to lead to an enhanced sensitivity to PARP inhibitors and 
platinum salts15. A key translational question that arises from our study is hence whether RCC patients with AC3 
exposure and other signs of “BRCAness” will in fact benefit from such therapies.
Another mutational signature that was frequently detected in our samples is AC5. The unique characteristic of 
ccRCCs to generally downregulate important metabolic pathways and instead rely on a small metabolic network 
not usually found in other tumors has recently been reported45. These metabolic changes were found to be asso-
ciated with a loss of the VHL tumor suppressor on chromosome 3p. In four of five RCCs analyzed in our study, 
we found histologically a clear cell phenotype and a corresponding loss of chromosome 3p (Suppl. Fig. 2). All of 
these tumors showed a ubiquitous presence of mutational signature AC5. In only one tumor (RCC-VTT-04), AC5 
was undetectable in one of the specimens (tumor (3)) and detected at a low level in another specimen (tumor (1)). 
This RCC was a papillary RCC type II with the characteristic SETD2 and NF2 mutation33,34. The fact that AC5 
was detectable in this tumor without VHL mutation suggests that other mechanisms may contribute to its origin 
as well. AC5 has been reported to be high in papillary RCC as well as in ccRCC39 before and our results confirm 
this notion. AC5 has also been suggested to represent a clock-like signature39. Patient RCC-VTT-04, the patient 
with papillary RCC type II and heterogeneous AC5 exposure, was the oldest of the five patients analyzed. This 
suggests that the tissue of origin and the cancer entity have an important modulating effect on and may even out-
weigh the clock-like nature of AC5. The biological basis of signature AC5, which can be detected in many human 
cancers, is still poorly understood and future studies are needed to fully understand the role of AC5 as well as 
other mutational signatures in tumor development and progression46. Although it has recently been suggested 
that mutational signatures can have a certain degree of gender specificity47, the study population used here is too 
small to draw any conclusions in that respect.
Our report on the mutational landscape of RCC with VTT using multiregion whole exome sequencing of the 
VTT provides important insights into the natural history of this unique growth pattern. Our results are in line 
with a previous report of heterogeneous mutations in a venous thrombus from a single RCC patient2. We provide 
the evidence for a “BRCAness” signature in RCC, which may have important translational and clinical implica-
tion and may lead to novel treatment modalities such as PARP inhibitors, platinum salts and others in a selected 
group of patients. Pre-clinical studies to test this notion are urgently warranted.
References
 1. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 
883–892 (2012).
 2. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. 
Genet. 46, 225–233 (2014).
 3. Pouliot, F., Shuch, B., Larochelle, J. C., Pantuck, A. & Belldegrun, A. S. Contemporary management of renal tumors with venous 
tumor thrombus. J. Urol. 184, 833–41; quiz 1235 (2010).
 4. Martínez-Salamanca, J. I. et al. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium 
(IRCC-VTC). Curr Urol Rep 15, 404 (2014).
 5. Psutka, S. P. & Leibovich, B. C. Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma. Ther 
Adv Urol 7, 216–229 (2015).
 6. Bertini, R. et al. Impact of venous tumour thrombus consistency (solid vs friable) on cancer-specific survival in patients with renal 
cell carcinoma. Eur. Urol. 60, 358–365 (2011).
 7. Weiss, V. L. et al. Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (RCC). BJU 
Int. 113, 209–217 (2014).
 8. Mager, R. et al. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on 
cancer specific survival. J Surg Oncol https://doi.org/10.1002/jso.24395 (2016).
 9. Reese, A. C., Whitson, J. M. & Meng, M. V. Natural history of untreated renal cell carcinoma with venous tumor thrombus. Urol. 
Oncol. 31, 1305–1309 (2013).
 10. Kirkali, Z. & Van Poppel, H. A critical analysis of surgery for kidney cancer with vena cava invasion. Eur. Urol. 52, 658–662 (2007).
 11. Haferkamp, A. et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J. 
Urol. 177, 1703–1708 (2007).
 12. Hoefflin, R. et al. Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity. Nat 
Commun 7, ncomms11845 (2016).
 13. Waclaw, B. et al. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature 525, 261–264 
(2015).
 14. Almendro, V. et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 74, 1338–1348 (2014).
 15. Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152–1158 (2017).
 16. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
 17. Jones, D. T. W. et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 100–105 (2012).
 18. Jones, D. T. W. et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 45, 927–932 (2013).
 19. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. 
Nucleic Acids Res. 38, e164 (2010).
www.nature.com/scientificreports/
1 1Scientific REPoRTS |  (2018) 8:7477  | DOI:10.1038/s41598-018-25544-z
 20. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308–311 (2001).
 21. 1000 Genomes Project Consortium et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 
(2012).
 22. Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing 
applications. Nat. Genet. 46, 912–918 (2014).
 23. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
 24. Hübschmann, D., Gu, Z. & Schlesner, M. YAPSA: Yet Another Package for Signature Analysis. R package version 1.0.0. (2015).
 25. Wang, Y., Lawson, C. L. & Hanson, R. J. lsei: Solving Least Squares Problems under Equality/Inequality Constraints. R package 
version 1, 1–1 (2015).
 26. Gehring, J. S., Fischer, B., Lawrence, M. & Huber, W. SomaticSignatures: inferring mutational signatures from single-nucleotide 
variants. Bioinformatics 31, 3673–3675 (2015).
 27. Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: Genome-Wide Copy Number Detection and Visualization from 
Targeted DNA Sequencing. PLoS Comput. Biol. 12, e1004873 (2016).
 28. Olshen, A. B. et al. Parent-specific copy number in paired tumor-normal studies using circular binary segmentation. Bioinformatics 
27, 2038–2046 (2011).
 29. Popova, T. et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 
inactivation. Cancer Res. 72, 5454–5462 (2012).
 30. Abkevich, V. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian 
cancer. Br. J. Cancer 107, 1776–1782 (2012).
 31. Jiang, Y., Qiu, Y., Minn, A. J. & Zhang, N. R. Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal 
evolutionary history by next-generation sequencing. Proceedings of the National Academy of Sciences 113, E5528–37 (2016).
 32. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 
43–49 (2013).
 33. Cancer Genome Atlas Research Network et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N. 
Engl. J. Med. 374, 135–145 (2016).
 34. Durinck, S. et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat. Genet. 47, 13–21 
(2015).
 35. Zhang, D., Zaugg, K., Mak, T. W. & Elledge, S. J. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage 
response. Cell 126, 529–542 (2006).
 36. Niedernhofer, L. J. et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced 
double-strand breaks. Mol. Cell. Biol. 24, 5776–5787 (2004).
 37. Song, W., Pascal, J. M., Ellenberger, T. & Tomkinson, A. E. The DNA binding domain of human DNA ligase I interacts with both 
nicked DNA and the DNA sliding clamps, PCNA and hRad9-hRad1-hHus1. DNA Repair (Amst.) 8, 912–919 (2009).
 38. Burrell, R. A. et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 494, 492–496 (2013).
 39. Alexandrov, L. B. et al. Clock-like mutational processes in human somatic cells. Nat. Genet. 47, 1402–1407 (2015).
 40. Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110–120 (2016).
 41. Tutt, A. et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between 
repeated sequences. EMBO J. 20, 4704–4716 (2001).
 42. Xia, F. et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end 
joining. Proc. Natl. Acad. Sci. USA 98, 8644–8649 (2001).
 43. Moynahan, M. E., Pierce, A. J. & Jasin, M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 7, 
263–272 (2001).
 44. Dietz, S. et al. Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under 
tyrosine kinase inhibitor therapy. Oncotarget https://doi.org/10.18632/oncotarget.18200 (2017).
 45. Gatto, F., Nookaew, I. & Nielsen, J. Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell 
renal carcinoma. Proceedings of the National Academy of Sciences 111, E866–75 (2014).
 46. Supek, F. & Lehner, B. Clustered Mutation Signatures Reveal that Error-Prone DNA Repair Targets Mutations to Active Genes. Cell 
170, 534–547.e23 (2017).
 47. Letouzé, E. et al. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. 
Nat Commun 8, 1315 (2017).
 48. Novick, A. C., Streem, S. B., Pontes, J. E. & Stewart, B. H. Stewart’s Operative urology. (1989).
Acknowledgements
We would like to thank the tissue bank of the National Center for Tumor Diseases Heidelberg for the procurement 
of tissue samples. The results shown here are in part based upon data generated by the TCGA Research network: 
http://cancergenome.nih.gov/. This work was supported by the Wilhelm Sander-Stiftung, the Medical Faculty 
Heidelberg and an internship by the International Federation of Medical Students Associations (to L.V.C.). D.H. 
is a member of the Hartmut Hoffmann-Berling International Graduate School of Molecular and Cellular Biology 
(HBIGS) and of the M.D./Ph.D.-program of the University of Heidelberg.
Author Contributions
S.D., M.Ho., H.S. and M.S. conceived and jointly supervised the study; G.W., D.H. and K.K. performed the 
bioinformatic analyses; D.H. performed the analysis of mutational signatures; Y.T., M.He., L.V.C., L.T. performed 
experiments; C.N., C.P., C.Ga., T.K., J.N.D., G.H., D.T., B.H., S.Pa., D.J., and C.Gr. enrolled subjects and collected 
and contributed clinical data; K.W., A.S., and W.R. contributed pathology information; S.P and A.D. gave 
important advice on data analysis and interpretation; R.E. and M.S. supervised the bioinformatics analyses; S.D. 
supervised the research and wrote, together with G.W. and D.H., the first draft of the manuscript; all authors 
contributed to the editing of the manuscript and approved the final version.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-25544-z.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
1 2Scientific REPoRTS |  (2018) 8:7477  | DOI:10.1038/s41598-018-25544-z
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
